feed,title,long_url,short_url
FortuneBusinessInsights,Multiple Sclerosis Drugs Market to Exhibit 5.9% CAGR from 2023 to 2030; EMA and U.S. FDA Accept Ozanimod Applications for Treatment of RMS and RRMS,https://www.fortunebusinessinsights.com/press-release/multiple-sclerosis-drugs-market-9105,https://da.gd/7sjB
